Synageva BioPharma (GEVA -4.3%) slides after its Q4 beats on revenue but comes up short on a per share basis. Despite the miss, Piper Jaffray lifts its price target from $53 to $57, citing optimism over upcoming Phase 1/2 data on LAL-D. Wedbush also ups its target to $55 as well.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharmaat Benzinga.com (Fri, 10:34AM)
at CNBC.com (Jan 15, 2015)
at Benzinga.com (Jan 12, 2015)
at Nasdaq.com (Jan 8, 2015)
at Benzinga.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs